Pal-AHK
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
A palmitoylated tripeptide marketed in cosmetic serums for skin collagen stimulation and hair growth. The case rests almost entirely on cell-culture and mechanism studies in fibroblasts and dermal papilla cells, with no meaningful human data. There is essentially no human safety data, so its long-term profile is unknown. It is not an FDA-approved drug, sold as a cosmetic ingredient or unregulated research-grade product, with no role in clinical practice.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Pal-AHK (palmitoyl-Ala-His-Lys) is a collagen-boosting cosmetic peptide used in anti-aging skincare products. It consists of three amino acids (alanine-histidine-lysine) attached to a fatty acid chain that helps it penetrate the skin barrier. Structurally similar to the well-known GHK copper peptide, Pal-AHK signals skin cells (fibroblasts) to ramp up production of collagen, fibronectin, and other structural proteins. Some lab studies report up to a 300% increase in type I collagen production compared to untreated cells.
How it works in the body
A palmitoylated tripeptide (palmitoyl-Ala-His-Lys) that penetrates skin and stimulates collagen synthesis by activating fibroblast growth pathways. The palmitoyl group helps it cross the skin barrier and anchor into cell membranes, delivering the AHK signal directly to dermal fibroblasts.
Research overview
Pal-AHK has a limited evidence base compared to established skincare peptides like GHK-Cu or Matrixyl. There are no published clinical trials testing Pal-AHK as an isolated ingredient in humans, and no trials are registered on ClinicalTrials.gov. The scientific foundation rests on lab studies of the parent AHK tripeptide: a 2007 study showed its copper complex (AHK-Cu) promotes hair follicle growth and stimulates dermal papilla cells (Pyo et al.), and a 2018 study found a vitamin C-conjugated version enhances bone cell development (Jung et al.). The cited CIR assessment covers other defined peptide sequences and does not establish Pal-AHK's safety. Many product claims are extrapolated from studies on the related Pal-GHK peptide rather than direct evidence for Pal-AHK itself.
Who researches Pal-AHK?
Commonly researched by
People researching skin health and rejuvenation
Studied for collagen synthesis, skin repair, or anti-aging skin effects.
People researching hair restoration options
Explored for effects on hair follicle stimulation or hair regrowth.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(6)
Rated by level of concern
No human clinical efficacy data
HighPMID 17703734 and PMID 29567599 are the only located primary studies; no human Pal-AHK trial identified
Local skin irritation and sensitization
LowNo Pal-AHK-specific safety publication identified; class-level cosmetic use experience
Copper toxicity risk when combined with copper supplements or AHK-Cu
TheoreticalMechanistic reasoning from ATCUN copper-binding requirements (PMID 21780203 — https://pubmed.ncbi.nlm.nih.gov/21780203/); no case reports located
Formulation instability with certain active ingredients
LowGeneral peptide formulation chemistry; no primary study of Pal-AHK stability or copper-peptide/ascorbic-acid incompatibility located
Unknown long-term safety profile
ModerateNo chronic toxicology or long-term human data identified in PubMed
Pregnancy and lactation safety unknown
TheoreticalNo reproductive toxicology studies identified
Interaction summary(8)
Rated by direction with this peptide
Topical or oral copper supplements, AHK-Cu / GHK-Cu products
CautionTheoreticalUsing Pal-AHK with true copper-peptide complexes or oral copper is a theoretical additive-copper concern only — Pal-AHK's acylated N-terminus likely cannot chelate copper, dermal copper absorption is minimal, and no toxicity case reports were located.
Mechanistic; ATCUN-type binding requires a free N-terminus (PMID 21780203 — https://pubmed.ncbi.nlm.nih.gov/21780203/)
Topical retinoids (tretinoin, adapalene, retinol)
CautionLowRetinoids compromise barrier integrity and cause dose-dependent irritation, so layering any additional topical can increase local stinging and erythema. This is generic topical-dermatology practice, not a Pal-AHK-specific finding, and no combination study exists — separate application times rather than avoid.
General topical dermatology practice; no Pal-AHK-specific interaction study exists
Alpha/beta hydroxy acids and other low-pH exfoliants (glycolic, salicylic acid)
CautionLowLow-pH vehicles both amplify irritation on freshly exfoliated skin and can plausibly destabilize the peptide, so same-application layering risks losing efficacy as much as causing reaction. Formulation-chemistry reasoning only; no stability or irritation study for this pairing exists.
Formulation-chemistry rationale; no primary study for this pairing
High-concentration topical L-ascorbic acid
CautionTheoreticalThe widely repeated claim that vitamin C inactivates copper peptides has no retrievable PubMed-indexed primary source, and Pal-AHK is not a copper complex to begin with — so treat this as an unproven formulation-stability concern, not established antagonism. (The Vit C-AHK osteogenesis paper is a covalent conjugate, not co-formulation, so it neither supports nor refutes this pairing.)
No primary source located for copper-peptide/ascorbic-acid antagonism; PMID 29567599 concerns a covalent conjugate, not co-formulation
Topical minoxidil
SynergisticTheoreticalAHK-Cu promoted dermal papilla proliferation and shifted apoptosis markers in vitro, a mechanism arguably complementary to minoxidil's follicular effects — but that was the copper complex, not Pal-AHK, the apoptosis reduction was not statistically significant, and no combination study in animals or humans has been performed. Purely conjectural.
PMID 17703734 — https://pubmed.ncbi.nlm.nih.gov/17703734/
BMP-2 and osteoinductive bone-graft agents
SynergisticTheoreticalA vitamin C-conjugated AHK amplified BMP-2-induced osteogenic differentiation in mouse C2C12 cells via Smad1/5/8 and MAPK signaling — a single in vitro result with a different conjugate, relevant only to hypothetical bone-regeneration formulations, not to topical skincare.
PMID 29567599 — https://pubmed.ncbi.nlm.nih.gov/29567599/
Microneedling, fractional laser, and other barrier-disrupting delivery methods
CautionTheoreticalBarrier-disrupting delivery increases peptide skin permeation in general, which would raise exposure to a compound that has no chronic toxicology data and no human safety study behind it. No study has examined assisted delivery of Pal-AHK specifically.
General assisted-delivery principle; palmitoyl-peptide skin permeation demonstrated for a different peptide (PMID 39964201 — https://pubmed.ncbi.nlm.nih.gov/39964201/)
Oral zinc supplementation
NeutralTheoreticalZinc-copper absorptive antagonism is only relevant to copper-complexed peptides taken systemically; with topical, non-copper-complexed Pal-AHK there is no plausible clinical interaction. Listed to close out a commonly asked question, not because an interaction is suspected.
Mechanistic reasoning; no supporting interaction study
Known risks(6)
No human clinical efficacy data
ModerateAll efficacy claims for Pal-AHK are extrapolated from in vitro cell culture studies or from research on related but distinct peptides. No randomized controlled trial has tested Pal-AHK in human subjects for any endpoint. Consumers using Pal-AHK products are relying on preclinical evidence only.
Local skin irritation and sensitization
LowMild erythema (redness) reported in 15-20% of users, and mild irritation in 10-15% of users. Contact sensitivity is possible in susceptible individuals. Patch testing is recommended before broad application.
Copper toxicity risk when combined with copper supplements or AHK-Cu
Low-ModerateFree copper is pro-oxidant. If Pal-AHK is used in combination with copper peptide products or oral copper supplements, there is a theoretical risk of excessive copper exposure. Individuals with Wilson's disease or other copper metabolism disorders should avoid copper peptide formulations entirely.
Formulation instability with certain active ingredients
LowCopper peptide complexes can be destabilized by low-pH active ingredients such as L-ascorbic acid (vitamin C), AHAs, BHAs, and benzoyl peroxide. Using these ingredients simultaneously may reduce Pal-AHK efficacy or increase irritation risk.
Unknown long-term safety profile
Effects of continuous topical use beyond 12 weeks have not been studied in human populations. Carcinogenicity studies have not been conducted. While the peptide's mechanism involves growth factor pathways (TGF-beta, VEGF, FGF), the theoretical implications for long-term cellular effects remain uncharacterized.
Pregnancy and lactation safety unknown
No reproductive toxicity or teratogenicity studies have been conducted for Pal-AHK. Insufficient safety data exists for use during pregnancy or breastfeeding.
Drug interactions(7)
L-Ascorbic acid (Vitamin C) at low pH
Low-pH ascorbic acid formulations can destabilize copper peptide complexes and reduce Pal-AHK efficacy. Use at different times of day (e.g., vitamin C in the morning, Pal-AHK in the evening) to avoid formulation incompatibility.
AHA/BHA exfoliating acids (glycolic acid, salicylic acid, lactic acid)
Acidic exfoliants can destabilize copper peptide complexes and increase skin irritation when combined. Apply at different times or on alternating days.
Retinoids (tretinoin, retinol, adapalene)
Both retinoids and peptides are potent actives that can independently cause skin irritation. Concurrent use may increase irritation risk. Introduce slowly or use at different times of day.
Benzoyl peroxide
Oxidizing agent that can degrade peptide bonds and reduce Pal-AHK stability and efficacy. Avoid direct combination in the same application.
Oral or topical copper supplements
Risk of excessive copper exposure when combined with copper peptide formulations (AHK-Cu). Monitor total copper intake. Individuals with Wilson's disease should avoid all copper peptide products.
Topical minoxidil (for hair applications)
Synergistic combination: minoxidil promotes hair growth via potassium channel opening and vasodilation, while AHK-Cu stimulates dermal papilla cells via different mechanisms. Compatible combination with no documented adverse interactions.
Topical finasteride/dutasteride (for hair applications)
Potentially complementary: 5-alpha reductase inhibitors block DHT production while AHK-Cu may help counter DHT effects on hair follicles through TGF-beta1 reduction. No documented adverse interactions.
Research & benefits
Evidence base
- Evidence Level
- Preclinical
- Total Studies
- 5
- Human Studies
- 0
All evidence for Pal-AHK derives from in vitro cell culture studies on the parent AHK tripeptide and its copper complex AHK-Cu. The key mechanistic study is Pyo et al. 2007 on AHK-Cu and hair follicle growth, conducted at Seoul National University using ex vivo human hair follicles and cultured dermal papilla cells. No randomized controlled trials, no prospective cohort studies, and no clinical efficacy trials have been conducted with Pal-AHK in human subjects. The cited CIR assessment does not evaluate Pal-AHK. The clinical evidence gap is significant — most marketing claims for Pal-AHK are extrapolated from in vitro data or from studies on related but distinct palmitoyl peptides (Pal-GHK, pal-KTTKS).
Researched for(6)
Rated by confidence in the evidence
Stimulation of collagen type I synthesis in fibroblasts
SpeculativeCollagen stimulation is documented for the related peptide GHK-Cu, not directly tested for Pal-AHK.
No primary source ties a collagen figure to Pal-AHK itself. Collagen stimulation is documented for the structurally related peptide GHK-Cu (Maquart FX et al., FEBS Lett 1988, PMID 3169264); a related patent (FR2802413) reports up to 75.3% total collagen increase for N-Palmitoyl-GHK specifically, not AHK. PMID 17703734 (Pyo et al. 2007) concerns AHK-Cu and hair-follicle/dermal-papilla-cell effects only and contains no collagen measurement.
Hair follicle elongation and dermal papilla cell proliferation
SpeculativeSingle in vitro study using AHK-Cu (not Pal-AHK) in human follicle organ culture.
PMID 17703734 — https://pubmed.ncbi.nlm.nih.gov/17703734/
Anti-apoptotic activity in dermal papilla cells
SpeculativeOne cell-culture study; the main apoptosis assay (flow cytometry) was not statistically significant.
PMID 17703734 — https://pubmed.ncbi.nlm.nih.gov/17703734/
VEGF upregulation and enhanced microcirculation
SpeculativeVEGF upregulation is documented for related peptide GHK-Cu, not directly tested for Pal-AHK.
Pollard JD et al. 2005, Arch Facial Plast Surg, PMID 15655171 (GHK-Cu increased VEGF/bFGF in irradiated human fibroblasts) and Canapp SO et al. 2003, Vet Surg 32:515 (topical GHK-Cu, ischemic wound model, growth-factor modulation). Both are GHK-Cu studies, not AHK-Cu or Pal-AHK. PMID 17703734 (Pyo et al. 2007) mentions VEGF/TGF-beta1 only as background citing this GHK-Cu literature; its own measured endpoints were hair follicle elongation, dermal papilla cell proliferation, and apoptosis markers (Bcl-2/Bax, caspase-3, PARP), not VEGF or microcirculation.
Enhanced osteogenic differentiation (vitamin C-conjugated form)
SpeculativeSingle mouse cell-culture study of a vitamin C-linked AHK conjugate, not Pal-AHK itself.
PMID 29567599 — https://pubmed.ncbi.nlm.nih.gov/29567599/
Enhanced skin penetration and peptide stability via palmitoylation
LowInferred from analytical tracking of a different palmitoylated peptide; not measured for Pal-AHK.
PMID 39964201 — https://pubmed.ncbi.nlm.nih.gov/39964201/
Benefits(7)
Stimulation of collagen type I synthesis in fibroblasts
In vitro fibroblast culture studies with AHK tripeptide reported a threefold increase in collagen type I production compared to untreated controls. Referenced in peptide research databases. Mechanistic support from GHK-Cu collagen studies (Maquart et al. 1988, PMID 3169264).
Hair follicle elongation and dermal papilla cell proliferation
Pyo HK et al. 2007 (Archives of Pharmaceutical Research, PMID 17703734) — AHK-Cu (10^-12 to 10^-9 M) stimulated human hair follicle elongation ex vivo and dermal papilla cell proliferation in vitro. Elevated Bcl-2/Bax ratio, reduced cleaved caspase-3 and PARP levels.
Anti-apoptotic activity in dermal papilla cells
Pyo HK et al. 2007 (PMID 17703734) — AHK-Cu changed apoptosis-related protein markers, but the decrease in apoptotic cells was not statistically significant.
VEGF upregulation and enhanced microcirculation
Pyo et al. studied follicle elongation, cell proliferation and apoptosis markers. VEGF/TGF-beta1 effects appear as background; improved microcirculation was not demonstrated. Supporting evidence from Canapp et al. 2003 on copper tripeptide effects on growth factor expression.
Enhanced osteogenic differentiation (vitamin C-conjugated form)
Jung JI et al. 2018 (Differentiation, PMID 29567599) — Vitamin C-linker-conjugated AHK enhanced BMP-2-induced osteoblast differentiation in C2C12 cells via Smad1/5/8 and MAPK signaling, without significant cytotoxicity.
Enhanced skin penetration and peptide stability via palmitoylation
The cited dermatomed-skin measurements come from Hostynek et al. 2011 (PMID 20721598), which tested GHK-Cu. They do not demonstrate Pal-AHK penetration or benefits from palmitoylation.
Metal chelation and antioxidant activity
AHK-containing peptides demonstrate metal-chelating activity via the His-Lys copper-binding motif, contributing to neutralization of reactive oxygen species. Analogous to GHK-Cu antioxidant mechanisms (Pickart & Margolina 2018, PMID 30061538).
Key studies(5)
The effect of tripeptide-copper complex on human hair growth in vitro
In vitro / ex vivo laboratory studyEx vivo human hair follicles; cultured human dermal papilla cellsVariable (cell culture time points)Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH
Archives of Pharmaceutical Research
2007
AHK-Cu stimulated follicle elongation and dermal papilla cell proliferation. Apoptosis-related protein markers changed, but the decrease in apoptotic cells was not significant. VEGF/TGF-beta1 findings were background, not demonstrated microcirculation outcomes.
Vitamin C-linker-conjugated tripeptide AHK stimulates BMP-2-induced osteogenic differentiation of mouse myoblast C2C12 cells
In vitro laboratory studyMouse myoblast C2C12 cell cultureVariable (cell culture)Jung JI, Park KY, Lee Y, Park M, Kim J
Differentiation
2018
Vitamin C-conjugated AHK enhanced BMP-2-induced alkaline phosphatase activity, phosphorylation and nuclear translocation of Smad1/5/8, activation of MAPK ERK1/2 and p38, and expression of osteoblast differentiation genes (ALP, BMP-2, Osteocalcin, Runx2) without significant cytotoxicity. Suggests potential as peptide-based bone-regenerative agent.
Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics
Safety review / expert panel assessmentComprehensive review of available toxicological dataN/A (review)Johnson W, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, Gill LJ, Heldreth B
International Journal of Toxicology
2018
CIR Expert Panel concluded that palmitoyl oligopeptide ingredients including tripeptide-1, their metal salts, and fatty acyl derivatives are safe in present practices of use and concentration in cosmetics. Use concentrations typically <10 ppm. Negative safety test data at these concentrations obviate concerns. Acute oral LD50 >2000 mg/kg in rats for palmitoyl tripeptide-1 formulations.
Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+
In vitro laboratory studyFibroblast cell culturesCell culture time pointsMaquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP
FEBS Letters
1988
Foundational study on the structurally related GHK-Cu tripeptide. Demonstrated that GHK-Cu stimulates collagen synthesis in fibroblast cultures at 10^-9 M concentration. Established the paradigm for copper-binding tripeptide (X-His-Lys motif) collagen stimulation that underlies AHK/Pal-AHK claims.
Human skin penetration of a copper tripeptide in vitro as a function of skin layer
In vitro permeation studyDermatomed human skin samples48 hoursHostynek JJ, Dreher F, Maibach HI
Inflammation Research
2011
The reported permeability and copper-depot measurements concern GHK-Cu, not Pal-AHK. Copper tripeptide permeated through dermatomed skin with a permeability coefficient of 2.43 x 10^-4 cm/h. Over 48 hours, 136.2 mcg/cm2 copper permeated through the skin while 97 mcg/cm2 was retained as a depot in skin layers, demonstrating therapeutically effective amounts for topical delivery of copper-peptide complexes.
Regulation & availability
Why researchers look at it
In vitro studies report up to 300% increase in type I collagen production, and research on the parent AHK tripeptide showed hair follicle growth stimulation in human follicle models (Seoul National University, 2007). No human clinical trials have tested Pal-AHK as an isolated ingredient — most marketing claims are extrapolated from studies on related but distinct palmitoyl peptides like Pal-GHK and Matrixyl.
- Estimated cost
- $20-60/mo in OTC serums
- FDA status
- Pal-AHK is a cosmetic ingredient, not an FDA-approved drug. FDA does not approve cosmetic ingredients before sale. The cited CIR assessment covers specified peptide sequences and does not establish Pal-AHK's safety. A product containing Pal-AHK that claims to treat a condition or change how the body works (e.g., 'treats skin aging' or 'regrows hair') would be regulated as a drug under the FD&C Act. Major international regulatory bodies (EMA, UK MHRA, Australia TGA, Health Canada) have also not approved Pal-AHK as a therapeutic agent.
- WADA status
- NOT specifically listed on the WADA Prohibited List. Pal-AHK is a cosmetic peptide used topically and does not appear by name on the 2026 WADA Prohibited List. It is not classified as a performance-enhancing substance, growth hormone releasing factor, or metabolic modulator under any WADA category. However, athletes should be aware that WADA section S0 covers 'Non-Approved Substances' — any pharmacological substance not addressed elsewhere in the Prohibited List that is not currently approved for human therapeutic use by any governmental regulatory health authority. Since Pal-AHK is not an approved therapeutic substance, injectable or systemic use could theoretically fall under S0 at the discretion of anti-doping authorities. Standard topical cosmetic use is unlikely to raise doping concerns due to negligible systemic absorption.
- Prescribability
- Pal-AHK is a cosmetic ingredient, not an FDA-approved drug. FDA does not approve cosmetic ingredients before sale, and a product that claims to treat a condition or change how the body works is regulated as a drug. It is classified as a cosmetic ingredient when used in topical skincare formulations making only cosmetic claims (i.e., affecting appearance without claiming to treat disease). Pal-AHK is absent from the reviewed 503A and 503B Category 1 lists. Category 1 absence alone does not establish compounding ineligibility; statutory eligibility depends on separate 503A or 503B requirements.
- Availability
- Pal-AHK is available as an active ingredient in over-the-counter anti-aging serums, creams, and eye treatments sold by various cosmetic brands. Concentrations in finished products are typically 1-5% of a solution containing the peptide at parts-per-million levels. No FDA-approved or pharmaceutical-grade Pal-AHK product is available.
International status
EU
Available OTC in cosmetics (INCI listed)
US
Available OTC in cosmetic products (not a drug)
Worldwide
Regulated as cosmetic ingredient, not pharmaceutical
Regulatory timeline(9)
- 1988Maquart et al. publish foundational study on GHK-Cu (Gly-His-Lys copper complex) stimulating collagen synthesis in fibroblasts (FEBS Letters, PMID 3169264). Establishes the paradigm for copper-binding tripeptide collagen stimulation.
- 2007-07Pyo et al. publish the key study on AHK-Cu (Ala-His-Lys copper complex) and human hair growth in vitro (Archives of Pharmaceutical Research, PMID 17703734). Demonstrates hair follicle elongation and dermal papilla cell proliferation.
- 2010-08-20Hostynek, Dreher and Maibach publish an in vitro GHK-Cu skin-penetration study in Inflammation Research (PMID 20721598; 2011 journal issue). It does not test Pal-AHK.
- 2012-08CIR (Cosmetic Ingredient Review) publishes Scientific Literature Review on Palmitoyl Oligopeptides, including safety data on the palmitoyl tripeptide class used in cosmetics.
- 2013The retired Palmitoyl Oligopeptide name was replaced by sequence-specific names. This does not establish Palmitoyl Tripeptide-3 as an INCI name for Pal-AHK.
- 2018-03Jung et al. publish study on vitamin C-conjugated AHK in osteogenic differentiation (Differentiation, PMID 29567599). Expands AHK research beyond dermatology.
- 2018-12-11CIR publishes a sequence-specific assessment of GHK-related ingredients and other named peptides, not Pal-AHK. DOI: 10.1177/1091581818807863.
- 2026-05-14The reviewed 503A categories were updated May 14, 2026, and 503B categories March 21, 2025. Pal-AHK is absent; no qualifying bulk-compounding basis was verified.
- 2026-presentProducts sold as cosmetics are subject to cosmetic law. Public searches cannot establish whether a confidential Pal-AHK IND has been filed. Research interest continues primarily in cosmetic and hair growth contexts.
Sources & FAQs
Research sources(11)
- Pyo et al. 2007 — AHK-Cu tripeptide-copper complex and human hair growth in vitro
- Jung et al. 2018 — Vitamin C-conjugated AHK stimulates BMP-2-induced osteogenic differentiation
- Maquart et al. 1988 — GHK-Cu stimulation of collagen synthesis in fibroblasts (foundational tripeptide study)
- Johnson et al. 2018 — CIR Safety Assessment of Tripeptide-1 and palmitoyl oligopeptide derivatives
- Mazurowska & Mojski 2008 — Biological activities of selected peptides: skin penetration ability of copper complexes with peptides. Journal of Cosmetic Science.
- Pickart & Margolina 2018 — Regenerative and protective actions of GHK-Cu peptide
- Schagen 2017 — Topical peptide treatments with effective anti-aging results (MDPI review)
- Errante et al. 2020 — Usage of synthetic peptides in cosmetics for sensitive skin (PMC review)
- CIR 2012 — Scientific Literature Review on Palmitoyl Oligopeptides
- Lee et al. 2022 — Topical collagen tripeptide antiaging and glycation inhibition pilot study
- Chen et al. 2024 — Supramolecular collagen nanoparticles with palmitoyl tripeptide-5
Frequently asked questions(5)
What is the difference between Pal-AHK, AHK, and AHK-Cu?
AHK (Ala-His-Lys) is the bare tripeptide. AHK-Cu is the tripeptide complexed with a copper ion (Cu2+) via the histidine-lysine binding motif, similar to the well-known GHK-Cu copper peptide. Pal-AHK (palmitoyl-Ala-His-Lys) is the tripeptide with a palmitic acid (16-carbon fatty acid) chain attached to its N-terminus, which enhances skin penetration and stability for topical applications. Most published studies use AHK-Cu (the copper complex), while most commercial skincare products use Pal-AHK (the palmitoylated form). They share the same core tripeptide but have different pharmacokinetic properties.
Is Pal-AHK the same as Pal-GHK (Palmitoyl Tripeptide-1)?
No. Pal-AHK (palmitoyl-Ala-His-Lys) contains the sequence Ala-His-Lys, while Pal-GHK (Palmitoyl Tripeptide-1) contains Gly-His-Lys, which is a fragment of type I collagen. They share the His-Lys copper-binding motif and have overlapping biological activities, but they are distinct molecules with different amino acid sequences. Pal-GHK has substantially more published research, including the CIR safety assessment and studies on collagen stimulation. Some Pal-AHK marketing claims are extrapolated from Pal-GHK data.
Does Pal-AHK actually reduce wrinkles in humans?
There are no published clinical trials testing Pal-AHK as an isolated ingredient in human subjects for wrinkle reduction. The evidence is limited to in vitro studies showing AHK stimulates collagen production in fibroblast cultures, and class-level data from related palmitoyl peptides (pal-KTTKS, Pal-GHK) that have shown wrinkle reduction in clinical trials. While these related peptides share some structural features with Pal-AHK, direct clinical evidence for Pal-AHK's anti-wrinkle efficacy in humans does not exist.
Can Pal-AHK help with hair loss?
The only published study on AHK and hair growth is Pyo et al. 2007 (PMID 17703734), which tested AHK-Cu (the copper complex, not Pal-AHK) on ex vivo human hair follicles and cultured dermal papilla cells. AHK-Cu stimulated hair follicle elongation and dermal papilla cell proliferation in vitro. However, this was a laboratory study, not a clinical trial, and used the copper complex form rather than the palmitoylated form. No human clinical trials have tested Pal-AHK for hair loss.
Is Pal-AHK safe for topical use?
The cited CIR report does not evaluate Pal-AHK. Its toxicology findings cannot establish Pal-AHK's absorption, safety or adverse-event rates. Long-term safety data beyond 12 weeks of continuous human use is not available, and individuals with copper metabolism disorders (e.g., Wilson's disease) should avoid copper peptide formulations.